Sarah Yim, MD
There’s a lot of changes coming up next, and we’re looking forward to continuing to work with stakeholders in terms of education, outreach, and regulatory science, as well as advancing the development of interchangeable rules.
Sarah Yim, MD, provided a point-by-point overview of the FDA's efforts to clarify the role of the interchangeable biosimilar designation, improve communication with manufacturers, and pay for biosimilar regulatory reviews.
With the COVID-19 pandemic more under control and the FDA settling back into its normal routines, the federal agency has had more to say lately about its efforts to develop the biosimilar market and usher more of these drugs to market.
At the GRx+Biosims 2021 meeting of the Association for Accessible Medicines this week, multiple FDA representatives, including Acting Commissioner Janet Woodcock, MD, delivered addresses intended to update the biosimilar development community on the FDA’s efforts to work the bugs out of the biosimilar development review process.
This included a talk by Sarah Yim, MD, director of the Office of Therapeutic Biologics and Biosimilars at the FDA’s Center for Drug Evaluation and Research, who focused on efforts to clarify how the interchangeable designation will be applied and how the FDA is improving manufacturer communication and timelines for biosimilar application review processes.
Interchangeability is granted for biosimilars whose developers have completed patient-switching studies involving multiple changes from reference product to biosimilar and back again. In the patient sense, it means that their pharmacist can give them the biosimilar instead of the reference brand without having to consult with the physician.
But in the manufacturing and policy community, questions have arisen that focus on whether interchangeability will apply across reference product indications and what happens if the method of biosimilar administration evolves, such as from prefilled syringe to wearable applicator, or if something changes with the reference product. Answers to these questions were not spelled out in the FDA’s original guidance on interchangeables.
“We’re going to do some things to help advance the development of interchangeable biosimilar biological products,” Yim said at GRx+Biosims. This will include development of a supportive regulatory science program and issuance of “foundational guidelines on container closure systems and device constituent parts for proposed interchangeable combination products,” she said.
Additional product support will involve development of guidelines for the labeling of interchangeable products, promotional labeling, and advertising considerations. Also in the works is guidance on supporting “postapproval manufacturing changes for different reporting categories for interchangeables,” Yim said.
“With this, we’re also going to be shooting for doing a scientific workshop on developing interchangeable products no later than October 2025,” she added.
In her presentation, Yim provided a brief timeline of recent biosimilar-related activities of significance to the commercial development sector:
With regard to the Purple Book enhancements, one of the chief improvements FDA officials touted at GRx+Biosims was the inclusion of a search engine function, Yim said. The book is now fully electronic and provides information on biosimilars that are on the market. Not only is it searchable, but data also can be sorted by fields selected by the user, FDA officials have said.
"Google Biosimilars"
Yim also noted that FDA biosimilar educational materials have been improved. “If you Google 'biosimilars,' you can actually bring up a link to our landing page, and this is full of additional links to take you to additional resources.”
These resources include calendar listings of upcoming events the FDA is organizing or participating in. “This year we have more than 2 dozen events with different stakeholders, ranging from health care professionals, patient groups, payers, health care policymakers, developers, and academics. In fact, being virtual probably made it a little easier for us to attend these different meeting events,” she said.
The FDA also has plans for provider and patient videos and a modular curriculum for health care professional development.
There’s a lot of changes coming up next, and we’re looking forward to continuing to work with stakeholders in terms of education, outreach, and regulatory science, as well as advancing the development of interchangeable rules.
As part of the BsUFA reviews, the FDA worked to establish timelines for labeling change approvals. These include safety information updates, added indications, and indication removals or deletions. Also, for meetings with developers that are narrowly focused on just a few key application elements, the FDA shortened the timelines for conducting these, providing a 60-day window.
The FDA also decided to reduce the background data, or “preliminary comparative analytical data,” that biosimilar applicants must bring to these meetings. “We’re also working on promoting best practices in communication during application reviews,” Yim said.
She said the FDA also is working toward issuing draft guidance on the use of alternative tools for factory inspections. Alternative tools would include means of reviewing manufacturer worthiness and quality preparations in lieu of actual site inspections, many of which were suspended during the COVID-19 pandemic because of potential COVID-19 exposure risk.
With the start of BsUFA III in 2023, the FDA will initiate demonstration projects, one of which will advance the development of interchangeable products and another that will address the efficiency of biosimilar product development. “The details of how these are going to be operated, operationalized, and implemented are still being worked out, but we hope to have everything up and running by the start [in 2023],” Yim said.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.